戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                                      Caco-2 cells treated with the chelate at calcium concentrations of 0
2                    These results were recapitulated in HK-2 cells treated with high glucose.
3 ocytes reduced alpha-smooth muscle actin expression in LX-2 cells treated with cholangiocyte-conditioned media.
4                                    IL-1-stimulated T/C-28a2 cells treated with an A2AR agonist had reduced ROS burden wit
5  These results were confirmed in photoreceptor-derived 661W cells treated with either H(2)O(2) or all-trans-retinal stres
6 ly profiled repair and metabolism in wild-type and Aag(-/-) cells treated with the alkylating agent methyl methanesulfona
7     All of these pathological events were rescued in acinar cells treated with a Piezo1 antagonist and in acinar cells fr
8 RISPR-Cas9 knockout screens in acute myeloid leukemia (AML) cells treated with various chemotherapies to map the drug-dep
9 s-triggered NF-kappaB, p38, and ERK pathways activation and cells treated with these pathway-specific inhibitors reduced
10 sed Nef-mediated down-regulation of MHC-I, but not CD4, and cells treated with CMA showed reduced formation of the Nef:MH
11 nvolved in actin core organization in podosomes, as well as cells treated with the inhibitors of the Arp2/3 complex, fail
12                                                        Beta cells treated with TM also exhibited concomitant alterations
13                           HSV-1 entry was unaltered in both cells treated with small interfering RNA (siRNA) to Rab5 or R
14 IP followed by sequencing (ChIP-seq) in MCF-7 breast cancer cells treated with the proteasome inhibitor MG132, and we fur
15    Meanwhile, the rate of de novo lipid synthesis in cancer cells treated with 17beta-estradiol was increased by 42%.
16  from the plasma membrane to endosomes in pancreatic cancer cells treated with the AXL ligand growth arrest-specific 6 (G
17                               Time lapse studies of E. coli cells treated with LL-37 show membrane discontinuities in the
18 ontent, and AKT or ERK1/2 signaling in human TSC2-deficient cells treated with GLPG1690.
19                                   Monocytes and endothelial cells treated with NMP express increased levels of KLF2, prod
20 s of BiP/GRP78, sXBP1 and GRP94 in human corneal epithelial cells treated with TNFalpha.
21                            No such synergy was observed for cells treated with alpha-TOH.
22                                                          GC cells treated with midostaurin or bosutinib significantly sup
23  the emergence of drug resistance in stem-like glioblastoma cells treated with RTK inhibitors.
24                                                     In HeLa cells treated with a peptide that disrupts Gle1 nucleocytopla
25 eatment, these responder patients, as well as hematopoietic cells treated with FeCl(3) and Deferasirox, showed a specific
26 inase (MAPK) and endothelial NO synthase (eNOS) in EA.hy926 cells treated with conditioned medium from Corin-siRNA- or AN
27 IC), a single enzyme in de novo purine biosynthesis, and in cells treated with a small molecule inhibitor of ATIC homodim
28 s PTPRF-mediated activation of Wnt signaling was blocked in cells treated with clathrin endocytosis inhibitor.
29 arized division, peptidoglycan organization is different in cells treated with PBP2 and PBP3-specific inhibitors.
30 sing siRNA prevents degradation of c-Jun, ETV4, and ETV5 in cells treated with either LT or the MEK1/2 inhibitor, U0126.
31                                         FRAP experiments in cells treated with the PKCalpha inhibitor Go6976 revealed tha
32     We observed similar regulation of Rapgef3 expression in cells treated with a highly specific inhibitor of LRRK2 prote
33 f a direct role for pol IV in double strand break repair in cells treated with double strand break-inducing antibiotics.
34 gle agent cisplatin-treated cells, the opposite was true in cells treated with cisplatin/JH-RE-06.
35 taining 24 Broccoli aptamers to be imaged in live mammalian cells treated with BI.
36                                       Murine and human mast cells treated with omeprazole exhibited diminished degranulat
37 recapitulated by simulating lipotoxicity in skeletal muscle cells treated with saturated FA, palmitate.
38                                                    NF2-null cells treated with an ERBB3-neutralizing antibody partially d
39              The phenotype and molecular characteristics of cells treated with LSD1 inhibitors were highly similar to cel
40 in in the nucleus, we estimated heterochromatin contents of cells treated with different drugs by quantifying the fluores
41         We analyzed matched time course RNAseq profiling of cells treated with single drugs and their combinations and fo
42                              Calreticulin-deficient ESCs or cells treated with an NFAT blocker had enhanced expression of
43               Uninfected and HIV-infected macrophages and T cells treated with trehalose exhibited increased markers of a
44                                   Here, we demonstrate that cells treated with pharmaceutical-grade rigosertib (>99.9% pu
45                              Further analysis revealed that cells treated with josamycin or other antibacterial agents ex
46 d caspase 3/7 activity in MDA-MB-231 cells in comparison to cells treated with DTX-loaded un-crosslinked MLNP (used as a
47 f cells treated with LSD1 inhibitors were highly similar to cells treated with UM171, an agent promoting expansion of HSC
48                                                        TOP2 cells treated with etoposide exhibit the same mutation signat
49 tic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a r
50 n 2 (PBP2) are unable to initiate polarized division, while cells treated with inhibitors that prevent peptidoglycan cros